Big news this week as PacifiCan announced the federal government will invest $11.1 million in funding to four tech companies across B.C., including LSBC member Kardium Inc - which will receive $5 million through the Business Scale-up and Productivity program. This follows last week’s announcement that the Government of Canada launched a public consultation to inform a new Pan-Canadian Genomics Strategy and has invited Canadians to share their view on the future of genomics in Canada. What a privilege it is to have an opportunity to have a voice - and we encourage those interested to share their input by the June 24th deadline.
SFU has an international reputation for research excellence and innovation programming, and they continue to build on this with two recent appointments: Michael Richards, SFU’s Archaeology Professor and Canada Research Chair in Archaeological Science, takes on the role of Associate Vice-President, Research as of July 1st, and Elicia Maine has been promoted to the inaugural role of Associate Vice-President of Knowledge Mobilization and Innovation.
We’d like to congratulate Asmita Dubey, Marie-Anne Aymerich, and Bryan Supran, who were appointed to the Designate Haleon Board, the new independent company to be formed following the demerger of the GSK Consumer Healthcare business, expected in July 2022. Add to this, we are thrilled to share that Anie Perrault has joined adMare BioInnovations as Vice President, Public Affairs and Communications. Congratulations also to Dr. Elizabeth Bryce, Dr. Andrea MacNeill and Cheyenne Johnson, researchers from Vancouver Coastal Health Research Institute, on being recipients of a 2022 YWCA Women of Distinction Award for their groundbreaking work in health care sustainability, substance use education and environmental infection control. And, kudos to Horizon Therapeutics, on winning an International Corporate Social Responsibility Excellence Award for its partnership with Gift of Adoption to co-create the #RAREis Adoption Fund. Finally, hats off to Response Biomedical, which celebrates their 30th anniversary this year, and the company’s evolution from a local cardiac point-of-care company to a global acute diagnostics player, saving lives all over the world!
We’d like to close off by thanking all of you for your ongoing contributions to our sector. Our members and sponsors play a vital role in what we are able to accomplish for the life sciences sector and we encourage you to reap the benefits of being a part of our community by attending some of our 30+ events each year, and utilizing our resources - such as our job board and member news section - to promote your company’s news. And, we’d love for you to join us for our LSBC Summer Social on June 23rd to kick off the summer season. Spaces are limited, so register today!
Until next week,
Wendy and the LSBC team
|
|
|
|
InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
InMed Pharmaceuticals Inc., a leader in the research, development, manufacturing and commercialization of rare cannabinoids, announced that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the issuance and sale of 4,079,256 of its common shares at a purchase price of $0.858 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules... READ MORE
|
|
|
|
Anie Perrault Joins adMare as Vice President, Public Affairs and Communications
adMare is pleased to announce the appointment of Anie Perrault, LL.L, ASC as Vice President, Public Affairs and Communications. In her new role, Ms. Perrault will oversee adMare’s communication and public affairs strategy, focused on advancing its mission of building companies, ecosystems, and talent. “Anie is a terrific addition to adMare’s senior management team and her deep experience building meaningful relationships and public policy will be invaluable to our vision of Canadian life sciences... READ MORE
|
|
|
|
Horizon Therapeutics plc Wins 2022 International CSR Excellence Award for #RAREis Adoption Fund
Horizon Therapeutics plc announced the company has won an International Corporate Social Responsibility Excellence Award for its partnership with Gift of Adoption to co-create the #RAREis Adoption Fund. As part of the award, Horizon will be formally recognized in the next CSR World Leaders report, which will be published in November 2022... READ MORE
|
|
|
|
GSK Announces Further Appointments to Designate Haleon Board
GSK plc has announced the appointments of Asmita Dubey, Marie-Anne Aymerich and Bryan Supran to the Designate Haleon Board, the new independent company to be formed following the demerger of the GSK Consumer Healthcare business, expected in July 2022. These appointments follow the appointment of Sir Dave Lewis as Non-Executive Chair Designate in December 2021 and the appointment of six directors in March 2022 and complete the formation of... READ MORE
|
|
|
|
Meet the VCHRI Recipients of the YWCA Women of Distinction Awards 2022
The YWCA Women of Distinction Awards is a nationally recognized event that celebrates extraordinary women leaders and businesses in Metro Vancouver. Congratulations to the VCHRI award recipients for their groundbreaking work in health care sustainability, substance use education and environmental infection control... READ MORE
|
|
|
|
New Pivotal Data Demonstrate Clinical Benefit of Roche’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People with Aggressive Lymphoma
Roche announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology Annual Meeting from 3-7 June and the European Hematology Association 2022 Congress from 9-12 June... READ MORE
|
|
|
|
Novartis Pluvicto™ Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA Positive Metastatic Castration-Resistant Prostate Cancer
Novartis announced that the US Food and Drug Administration approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic)... READ MORE
|
|
|
|
SFU Beedie Professor Elicia Maine named AVP of Knowledge Mobilization and Innovation for SFU
Elicia Maine, W. J. VanDusen Professor of Innovation and Entrepreneurship at SFU Beedie has been named the first AVP of Knowledge Mobilization and Innovation in the Office of the Vice-President, Research and International. An international expert on innovation and entrepreneurship, Maine is also the founder and academic director of SFU Beedie’s Invention to Innovation (i2I) program and the national Mitacs i2I skills training program... READ MORE
|
|
|
|
Innovative High-Growth Burnaby Businesses to Receive Government of Canada support
British Columbia’s small and medium-sized enterprises (SMEs) are critical to their communities – they create jobs, drive economic growth, and develop products and services that help solve local and global challenges. The Government of Canada believes in these companies. ..READ MORE
|
|
Research Associate, Analytical Chemistry
We are seeking an analytical chemistry-focused Research Associate to join our CMC team. Reporting to the Senior Scientist, CMC Analytical, the Research Associate will work flexibly across a number of small molecule drug development programs with an emphasis on developing analytical methods that will then be transferred, as appropriate, to external cGMP testing labs.
|
|
Laboratory Animal Technician
Let’s do this. Let’s change the world! In this vital role you will support animal-based studies, husbandry, and vivarium operations and also act as a back-up for technical and lab support for in-vivo research. We are all different, yet we all use our unique contributions to serve patients. The detail oriented professional we seek is a great teammate with these qualifications
|
|
Data Analyst
We are seeking a Data Analyst with a deep understanding of the drug development process. The ideal candidate will work cross-functionally within the company to analyze relevant market and business data in drug discovery and commercialization. Join us on our mission to bring new treatment options to patients by revolutionizing drug discovery!
|
|
Simon Fraser University’s Beedie School of Business has emerged as a dynamic teaching and learning setting with a reputation for producing global-class research for the knowledge economy.
Their undergraduate, graduate and PhD programs demonstrate a spirit of innovation, flexibility and relevance. Supported by extensive partnerships with public, private and not-for-profit organizations, their goal is to produce broadly educated, enterprising and socially responsible managers capable of making lasting contributions to their communities.
|
|
Vancouver Coastal Health Research Institute (VCHRI), a world leader in translational health research, is the research body of Vancouver Coastal Health Authority. VCHRI includes three of BC’s largest academic and teaching health sciences centres — Vancouver General Hospital, UBC Hospital, and GF Strong Rehabilitation Centre — as well as many other hospitals and public health agencies across Vancouver Coastal Health. VCHRI is academically affiliated with UBC Faculty of Medicine and is one of Canada’s top funded research centres receiving over 100 million in research funding annually.
|
|
|
|
Post A Job on the LSBC Website! |
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings EARNS a free repost on BioTalent Canada's The Petri Dish. After your first five reposts, you will also receive 25% off all job postings on The Petri Dish. Want more info? Contact Megan Pan -talent@lifesciencesbc.ca
|
|
|
|
|
|
|
